ライフサイエンスコーパス: anogenital

1 was anogenital location, but few cases were anogenital.

2 Concordant anogenital 9vHPV infection was more common among MSM tha

3 ysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.

4 man papillomavirus infection and its related anogenital abnormalities/cancer.

5 oduce viable herpes virions, particularly in anogenital and cervical tissues.

6 highlight differences between the effects of anogenital and cutaneous HPV on epithelial AKT activity

7 Other HPV-associated anogenital and head and neck cancers are predicted to af

8 papillomaviruses (HPVs) (e.g., HPV-16) cause anogenital and head and neck cancers, and low-risk HPVs

9 k human papillomaviruses (HPV) cause certain anogenital and head and neck cancers.

10 omote cervical cancer as well as a subset of anogenital and head and neck cancers.

11 ions with high-risk HPVs are associated with anogenital and head and neck cancers.

12 regulate epidermal differentiation and cause anogenital and head and neck squamous cell carcinomas (S

13 ervical cancer cases and a growing number of anogenital and oral cancers.

14 evalent oncogenic genotype in HPV-associated anogenital and oral cancers.

15 cervical cancers and an increasing number of anogenital and oral carcinomas, with most cases caused b

16 HPV-16, are etiologic agents of a variety of anogenital and oral malignancies, including nearly all c

17 HSV-1-seropositive healthy adults collected anogenital and oral swabs, respectively, 4 times per day

18 in types of HPV can cause cervical and other anogenital and oropharyngeal cancer, and other types of

19 al types of human papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous

20 es (HPVs) are etiological agents for several anogenital and oropharyngeal cancers.

21 PV), particularly HPV16, are major causes of anogenital and oropharyngeal cancers.

22 iruses (HPVs), particularly HPV16, can cause anogenital and oropharyngeal cancers.

23 spectively, whereas HPV16 dominates in other anogenital and oropharyngeal cancers.

24 papillomaviruses (HPVs) are a major cause of anogenital and oropharyngeal cancers.

25 fection that is a major cause of noncervical anogenital and oropharyngeal cancers.

26 l cervical cancers and a proportion of other anogenital and oropharyngeal cancers.

27 Clearance of anogenital and oropharyngeal HPV infections is attribute

28 the human papillomaviruses (HPVs) that cause anogenital and oropharyngeal malignancies must simultane

29 elated carcinomas and premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnos

30 nd are linked to several other tumors of the anogenital and oropharyngeal regions.

31 he high-risk human papillomavirus 16 infects anogenital and oropharyngeal sites, the cervical epithel

32 ithelial cancers, including those within the anogenital and oropharyngeal tracts.

33 e X-linked STAR (syndactyly, telecanthus and anogenital and renal malformations) syndrome, Alzheimer'

34 res include toe syndactyly, telecanthus, and anogenital and renal malformations.

35 Human papillomaviruses (HPV) cause cervical, anogenital, and oral cancers.

36 uman papillomaviruses (HPVs) cause cervical, anogenital, and oropharyngeal cancers.

37 ll cancer cases worldwide, notably cervical, anogenital, and oropharyngeal cancers.

38 oncogenic HPV type associated with cervical, anogenital, and oropharyngeal cancers.

39 relates with more time spent in sniffing the anogenital area of stressed mice, and the appearance of

40 sions (HSILs) as precursors to cancer in the anogenital area, and the microbiome is suggested to be a

41 ) but lichen sclerosus is most common in the anogenital area, where it causes intractable itching and

42 or clade 2b they are mainly localised to the anogenital area.

43 later malignancies of the head and neck and anogenital area.

44 mples were collected separately from several anogenital areas for detection of HPV6/11/16/18/31/33/35

45 icipants collected daily swabs from oral and anogenital areas for HSV detection with a quantitative p

46 ransplantation were significantly increased: anogenital cancer (HR, 3.13; confidence interval [CI], 1

47 ividuals with a history of an HPV-associated anogenital cancer and HIV-infected men are at increased

48 pport an important role for HPV infection in anogenital cancer at all sites.

49 y was designed to compare HPV exposure among anogenital cancer cases and matched controls.

50 Cases (1782) of anogenital cancer diagnosed in the Seattle area from 197

51 Women included had no history of any anogenital cancer or treatment for cervical dysplasia, h

52 were HIV negative and reported no history of anogenital cancer were recruited into the HPV Infection

53 p53 gene mutation is an infrequent event in anogenital cancer, apparently due to the action of HPV E

54 In addition to their role in anogenital cancer, human papillomaviruses (HPVs) are als

55 While many HR HPV types are common in anogenital cancer, over 90% of HPV-positive HNCs harbor

56 risk HPV types due to their association with anogenital cancer.

57 most infections are benign, some progress to anogenital cancer.

58 ial to target a wide range of HPVs linked to anogenital cancer.

59 Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12

60 viruses (HPVs) that cause cervical and other anogenital cancers also are found in approximately 25% o

61 Human papillomaviruses (HPV) cause anogenital cancers and anogenital HPV infection up-regul

62 PV) are the causative agents of cervical and anogenital cancers and are associated with 5% of all hum

63 s with GW have a long-term increased risk of anogenital cancers and head and neck cancers.

64 HPV-16), are etiologic agents of a subset of anogenital cancers and head and neck squamous cell carci

65 6, is central to the development of squamous anogenital cancers and their precursor lesions, termed "

66 roups primarily associated with cervical and anogenital cancers appear to follow two distinct evoluti

67 Anogenital cancers are associated with approximately 13

68 Cervical and anogenital cancers are induced by the high-risk types of

69 uman papillomaviruses (HPVs) associated with anogenital cancers are largely responsible for the oncog

70 Human papillomavirus-related anogenital cancers are theoretically preventable.

71 31, and 51 are the etiologic agents of many anogenital cancers including those of the cervix.

72 Conversely, the incidence of anogenital cancers may decline in the future among HIV-p

73 6 antibodies are present before diagnosis of anogenital cancers within the same cohort.

74 such as HPV16, cause cervical cancers, other anogenital cancers, and a subset of head and neck cancer

75 the vast majority of cervical cancers, other anogenital cancers, and a subset of head and neck squamo

76 the vast majority of cervical cancer, other anogenital cancers, and a subset of head and neck squamo

77 cancer and a significant proportion of other anogenital cancers, as well as both oral and pharyngeal

78 ), the causative agents of most cervical and anogenital cancers, encode three oncogenes.

79 h-risk human papillomaviruses (HR-HPV) cause anogenital cancers, including cervical cancer, and head

80 mavirus (HPV) is the main etiologic agent of anogenital cancers, including cervical cancer, but littl

81 aviruses (HPV) that cause cervical and other anogenital cancers.

82 HPV) infections are necessary causes of most anogenital cancers.

83 viruses are causative agents of cervical and anogenital cancers.

84 strongly associated with cervical and other anogenital cancers.

85 e the causative agents of cervical and other anogenital cancers.

86 responsible for the majority of cervical and anogenital cancers.

87 a and other HPV-associated oropharyngeal and anogenital cancers.

88 agent of warts and are associated with many anogenital cancers.

89 s, which are present in a high percentage of anogenital cancers.

90 illomaviruses (HPVs) are etiologic agents of anogenital cancers.

91 ses (HPVs) are implicated in the etiology of anogenital cancers.

92 luding a growing number of oropharyngeal and anogenital cancers.

93 the etiological agents of cervical and other anogenital cancers.

94 f anal cancer but rare for other HPV-related anogenital cancers.

95 The role of human papillomavirus (HPV) in anogenital carcinogenesis is firmly established, but evi

96 The majority of human anogenital carcinomas show evidence of papillomavirus in

97 isks (RRs) for concordant (CIS-CIS) types of anogenital (cervical, other female and male genital and

98 The results for anogenital CIS types suggest that life style related hum

99 n, and may lead to clinical sequelae such as anogenital condylomata and cervical squamous cell carcin

100 t human papillomavirus types correlated with anogenital cytologic abnormalities, an important area in

101 apillomavirus types and a high prevalence of anogenital cytologic abnormalities.

102 mporal fate maps, we present a new model for anogenital development and suggest that disruptions at s

103 ow the fate of posterior gut endoderm during anogenital development.

104 reduction in human papillomavirus-associated anogenital disease with both quadrivalent and bivalent v

105 fected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosu

106 Body mass, body fat, sex, anogenital distance (AGD) (a proxy for androgenization)

107 Normal reproductive tract development and anogenital distance (AGD) are programmed within the MPW,

108 asis of masculinization, as indicated by the anogenital distance (AGD) at birth and weaning, in the r

109 Anogenital distance (AGD) in animals is a sensitive biom

110 nal exposures and manifesting as a shortened anogenital distance (AGD) in male rats.

111 n and identified as bad actors for a shorter anogenital distance (AGD) in their baby boys.

112 Anogenital distance (AGD) is a sensitive biomarker of th

113 Anogenital distance (AGD), the distance from the anus to

114 h in male rats, all of which correlated with anogenital distance (AGD).

115 Two small studies report shorter anogenital distance among male infants with higher gesta

116 liver chemical profiles, masculinising fetal anogenital distance and greatly increasing the number of

117 Measurements of anogenital distance and penile dimensions were taken, an

118 f a stress-sensitive phenotype and shortened anogenital distance in adult F2-S males.

119 eriments, in utero exposure to DDE decreases anogenital distance in male offspring.

120 d spermatogenesis, preputial separation, and anogenital distance in males and day of vaginal opening

121 esis that in utero exposure to DDE decreases anogenital distance in newborn human males.

122 effects of weaned litter sex composition and anogenital distance on several life-history and fitness

123 d to reduced androgen action as reflected by anogenital distance or penile dimensions at birth.

124 stosterone action such as testis descent and anogenital distance remained normal.

125 In these models, anogenital distance serves as a measure of fetal androge

126 r of male and female offspring, body weight, anogenital distance, vaginal opening, testes descent, es

127 t the number of males in a litter influenced anogenital distance.

128 that masculinized females, those with larger anogenital distances, were less likely to survive their

129 omes, such as development of bronchiectasis, anogenital dysplasia, or invasive cancer.

130 esions caused by low-risk HPV-types, whereas anogenital dysplasias are potential cancer precursors as

131 cinomas (SCCs) arising from aerodigestive or anogenital epithelium that are associated with the human

132 Subjects underwent anogenital examinations and sampling of the penis, scrot

133 ated, we recommend that TOC be performed for anogenital gonorrhoea at least 7 or 14 days after admini

134 We included patients with anogenital gonorrhoea visiting the Sexually Transmitted

135 tients presenting with chronic pseudotumoral anogenital herpes simplex type 2 (HSV-2) infections were

136 promising vaccine candidates for controlling anogenital HPV disease and are now being evaluated as a

137 ort the concept of oral immunization against anogenital HPV disease and suggest that clinical studies

138 ined using pseudovirion-Luminex serology and anogenital HPV DNA using Linear Array.

139 o compare the potential of the full range of anogenital HPV genotypes to induce cytopathic effects, w

140 s study examined the determinants of initial anogenital HPV infection among teenage MSM.

141 ent strategies are not effective in clearing anogenital HPV infection and need improvement.

142 development of external genital lesions and anogenital HPV infection in boys and men.

143 International data on anogenital HPV infection incidence among men are limited

144 maviruses (HPV) cause anogenital cancers and anogenital HPV infection up-regulates AKT activity.

145 he most important modifiable risk factor for anogenital HPV infection.

146 Most anogenital HPV infections are cleared in less than two y

147 Incidence of incident-persistent (IP) anogenital HPV infections was evaluated among 295 men wh

148 types were determinants of current multiple anogenital HPV infections, abnormal cytology, and seropo

149 PV types is associated with current multiple anogenital HPV infections, abnormal cytology, and seropo

150 Antibodies against 15 anogenital HPV types and 6 cutaneous HPVs were determine

151 Presence of antibodies to multiple anogenital HPV types at baseline was associated strongly

152 Seropositivity against at least 3 anogenital HPV types is associated with current multiple

153 Presence of antibodies to >=3 anogenital HPV types tended to persist over time.

154 ule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased inci

155 We find that, in contrast to anogenital HPVs, cutaneous HPV8 early genes down-regulat

156 Infection with high-risk anogenital HPVs, such as HPV type 16 (HPV16), is associa

157 Female PHIV were at higher risk of having anogenital HR-HPV acquisition and persistence.

158 Anogenital HSV-2 cultures were positive on 405 (9.7%) of

159 y of resiquimod 0.01% gel for reducing human anogenital HSV-2 mucosal reactivation.

160 ation (CRT) and is typically associated with anogenital human papilloma virus infection.

161 nitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in H

162 er risk than uninfected youth for persistent anogenital human papillomavirus (HPV) infection, due to

163 er risk than uninfected youth for persistent anogenital human papillomavirus (HPV) infection, due to

164 Anogenital human papillomavirus (HPV) is common among me

165 Anogenital human papillomavirus infection remains highly

166 omavirus burden in HIV-infected individuals; anogenital human papillomavirus types and type-specific

167 The incidence of anogenital human papillomavirus-related cancers remains

168 In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate

169 24 (93%) of 134 individuals and described as anogenital in 95 (74%) of 129 and as vesiculopustular in

170 netic backgrounds, suggesting that orofacial/anogenital infections derived from the same virus lineag

171 As the modes of transmission of anogenital infections with HPV and HSV are unclear, an e

172 Sublineages B1 and B3 were associated with anogenital infections, indicating a potential lesion-spe

173 n areas of somatosensory nuclei that receive anogenital input together with the temporal corresponden

174 the maximum dose in 29 women with high-grade anogenital intraepithelial neoplasia (AGIN).

175 who treat anogenital warts, oral warts, and anogenital intraepithelial neoplasias (eg, cervical intr

176 including proximity, approach, huddling, and anogenital investigation in response to novel conspecifi

177 portance: Human papillomavirus (HPV)-induced anogenital lesions are very frequent in men who have sex

178 y improve our ability to accurately diagnose anogenital lesions due to herpes infection.

179 Four of seven patients with two distinct anogenital lesions had different HPV types in the lesion

180 08 participants (174 men and 334 women) with anogenital lesions were included; 260 HSV-2 and 73 HSV-1

181 Anatomically, anogenital lesions were reflective of sexual practices:

182 Paired samples from anogenital lesions were tested using the BD ProbeTec HSV

183 tients developed chronic, hypertrophic HSV-2 anogenital lesions with multilesional presentation in 7

184 rash (with 64% having <=10 lesions), 73% had anogenital lesions, and 41% had mucosal lesions (with 54

185 rimary syphilis is characterized by painless anogenital lesions.

186 The treatment of choice for anogenital lichen sclerosus is potent topical corticoste

187 on, perineural invasion, and ear, temple, or anogenital location were risk factors associated with po

188 azard ratio, 3.6 [95% CI, 1.1-12.0]), as was anogenital location, but few cases were anogenital.

189 a new tool for investigating the etiology of anogenital malformations in humans.

190 Sixteen anogenital malignancies (1.6%) were found: vulva (n=6),

191 A high number of anogenital malignancies developed in our cohort, which a

192 omaviruses (HPV) which are commonly found in anogenital malignancies express a viral E7 oncoprotein w

193 and likely contribute to the development of anogenital malignancies in vivo.

194 le renal transplant recipients who developed anogenital malignancies were retrospectively analyzed.

195 o develop human papillomavirus (HPV)-related anogenital malignancies.

196 tion to prevent morbidity and mortality from anogenital malignancies.

197 Genus alpha genotypes generally infect the anogenital mucosa, and a subset of these HPV are a neces

198 iate surrogate biomarkers for HPV-associated anogenital neoplasia trials.

199 factor in determining the natural history of anogenital neoplasia.

200 We review the recent literature on anogenital neoplasms in AIDS, with emphasis on cancers a

201 Most anogenital neoplasms occurring with increased frequency

202 he efficacy of HAART therapy for HPV-induced anogenital neoplasms, despite efficacy in improving dise

203 ch as mounting, pelvic thrust, solicitation, anogenital olfactory investigation, and emission of comp

204 ever the lineage of cells that gives rise to anogenital organs remains poorly understood.

205 f anorectal and genitourinary (collectively, anogenital) organs occur at a high frequency in humans,

206 Disruption of Shh function during the anogenital phase causes coordinated anorectal and genito

207 on is divisible into two temporal phases; an anogenital phase, during which Shh regulates outgrowth a

208 A clinical overview of female anogenital posttransplantation malignancies and possible

209 HPV)-related cutaneous and genital warts and anogenital (pre)cancer.

210 d risk of human papillomavirus (HPV)-related anogenital (pre)cancers, including anal high-grade intra

211 e 16 have been implicated in the etiology of anogenital premalignant and malignant lesions.

212 human papillomaviruses (HPVs) are linked to anogenital preneoplastic lesions and cancer.

213 and 10(3.3) copies/mL, respectively, during anogenital reactivation and 10(3.7) and 10(3.0) copies/m

214 Lesions were reported in only 3 (7%) of 44 anogenital reactivations and 1 (8%) of 13 oral reactivat

215 Twenty-four percent of anogenital reactivations and 21% of oral reactivations l

216 l reactivations lasted < or =6 h, and 49% of anogenital reactivations and 39% of oral reactivations l

217 ted high-grade lesions and carcinomas in the anogenital region and oropharynx between 1990 and 2015 w

218 The entire anogenital region and semen were sampled.

219 cell carcinomas (SCCs) of the head and neck, anogenital region and skin.

220 at the mucosal sites including those of the anogenital region and the oral cavity.

221 ne, spinal cord, adrenal cortex, and the uro-anogenital region in the neonatal AVPR1A WT mouse, as it

222 s; 141 (78%) participants had lesions in the anogenital region, and 78 (43%) in the oral and perioral

223 risk of carcinomas of the head and neck and anogenital region, and a small continuing risk of leukem

224 t receive somatosensory information from the anogenital region.

225 ndrome, which is characterized by hand/foot, anogenital, renal, and ear anomalies, including sensorin

226 noncutaneous squamous cell carcinoma (SCC), anogenital SCC, inability to extract cSCC data from othe

227 Our results underline the importance of anogenital screening and monitoring before and periodica

228 ty-three men in 2 US cities were tested at 6 anogenital sites and in semen for 37 types of HPV.

229 or HPV infection that collected samples from anogenital sites and used PCR or hybrid capture 2 techni

230 association of HPV DNA with cancer at other anogenital sites has produced less consistent results.

231 HPV16 were most likely to occur at multiple anogenital sites in HM and MSM, with strong agreement ob

232 revalence of concordant 9vHPV infection at 2 anogenital sites was 3.7% among HM and 9.1% among MSM, a

233 ed States for 37 HPV types in samples from 5 anogenital sites.

234 d risk of HPV-related cancer across multiple anogenital sites.

235 in itching, pain, edema, and staining of the anogenital skin associated with the active treatment.

236 lammatory disease that most commonly affects anogenital skin of postmenopausal women.

237 hyperkeratosis confined to palms, soles, and anogenital skin, whereas the other two had more severe,

238 detected on 12% of days (IQR: 2 to 25%) from anogenital specimens.

239 s a known risk factor for the development of anogenital squamous cell carcinomas (SCCs).

240 velop head and neck (HNSCC), oesophageal and anogenital squamous cell carcinomas(8) (SCCs).

241 sions were classified according to the Lower Anogenital Squamous Terminology (LAST) in low-grade (LSI

242 e first target cells to encounter HIV in the anogenital stratified squamous mucosa during sexual tran

243 HSV-2-seropositive Ugandan adults collected anogenital swab specimens for HSV DNA quantification by

244 Specimens included daily anogenital swabs (for HSV DNA polymerase chain reaction

245 Mixed anogenital swabs and cervical secretions were self-colle

246 weekly for 3 weeks and then collected daily anogenital swabs for 60 days for HSV DNA polymerase chai

247 ymptomatic genital HSV-2 infection collected anogenital swabs for HSV-2 DNA polymerase chain reaction

248 prepare infectious stocks of two additional anogenital tissue-targeting human papillomaviruses (HPVs

249 Our findings reveal that epidermal DCs in anogenital tissues potentially play a key role in sexual

250 LCs, epidermal CD11c(+) DCs are enriched in anogenital tissues where they preferentially interact wi

251 cinoma and a significant percentage of other anogenital tract and oral carcinoma.

252 They are the causative agents of anogenital tract and some oropharyngeal cancers.

253 et of human papillomaviruses that infect the anogenital tract and the upper aero-digestive tract is t

254 h as HPV-16 and HPV-18 cause the majority of anogenital tract carcinomas, including cervical cancer,

255 ontribute to a number of other tumors of the anogenital tract, as well as oral cancers.

256 PV) types, including the oral cavity and the anogenital tract.

257 ical agents of cancers of the oropharynx and anogenital tract.

258 HPV infections were analyzed in all primary anogenital tumors and possible (multifocal) premalignanc

259 fections and human papillomavirus-associated anogenital tumors are more prevalent in HIV-infected tha

260 espite highly active antiretroviral therapy, anogenital tumors may continue to increase in this popul

261 Among boys aged 15-19 years anogenital wart diagnoses decreased significantly by 48%

262 Anogenital wart diagnoses decreased significantly by 67%

263 inst human papillomavirus on HPV infections, anogenital wart diagnoses, and cervical intraepithelial

264 PV-related endpoint (genital HPV infections, anogenital wart diagnoses, or histologically confirmed C

265 nfection (RR 0.50, 95% CI 0.34-0.74]) and in anogenital warts (0.86 [95% CI 0.79-0.94]) occurred in g

266 pared with participants without a history of anogenital warts (17 of 6132 [0.3%]) (P < .001).

267 Trends in the annual prevalence of anogenital warts (AGW) from 2010-2016 were described by

268 Anogenital warts (AGWs) are considered benign lesions ca

269 guidelines on human papillomavirus (HPV) and anogenital warts (AGWs), a review of the literature was

270 en therapy has been used in the treatment of anogenital warts (AGWs), but it has not been compared wi

271 Condylomata acuminata (anogenital warts [AGWs]) are prevalent in human immunode

272 History of smoking and anogenital warts and blood specimens for measurement of

273 with men (MSM) have a high lifetime risk of anogenital warts and cancers related to infection with h

274 omaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas.

275 ogram will reduce the number of diagnoses of anogenital warts and cervical intraepithelial neoplasia

276 ogram will reduce the number of diagnoses of anogenital warts and cervical intraepithelial neoplasia

277 e 6 (HPV6) is the major etiological agent of anogenital warts and laryngeal papillomas and has been i

278 avirus 11 (HPV11) is an etiological agent of anogenital warts and laryngeal papillomas and is include

279 Substantial declines in anogenital warts and male HPV-related cancer incidence a

280 Anogenital warts are a common disorder associated with s

281 imes higher in individuals with a history of anogenital warts compared with individuals without a his

282 riods by 68% (RR 0.32, 95% CI 0.19-0.52) and anogenital warts decreased significantly by 61% (0.39, 0

283 ions and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and

284 49.9 [12.7] years), and 383 (5.9%) developed anogenital warts during the study period.

285 Anogenital warts in patients who are HIV+ should be eval

286 Thus, topical imiquimod treatment of anogenital warts led to significant increases in local p

287 counsel individuals living with HIV who have anogenital warts on this risk.

288 uded testing for HPV infection in women with anogenital warts or other sexually transmitted diseases,

289 Additionally, significant reductions in anogenital warts were also reported in boys younger than

290 Patients who were diagnosed with anogenital warts were more likely to subsequently develo

291 come countries: 23 for HPV infection, 29 for anogenital warts, and 13 for CIN2+.

292 ctiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous le

293 ast one HPV-related endpoint: HPV infection, anogenital warts, and high-grade cervical lesions.

294 transmission to healthcare workers who treat anogenital warts, oral warts, and anogenital intraepithe

295 , and other types of HPV are associated with anogenital warts.

296 PV 6 and 11, which cause 90% of the cases of anogenital warts.

297 WIL) from patients with clinically diagnosed anogenital warts.

298 mpared with individuals without a history of anogenital warts.

299 than 18 years with between 2 and 50 external anogenital warts.

300 e effective than placebo in the treatment of anogenital warts.